Kentaro Kawakami

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

K. Yamazaki, Michitaka Nagase, H Tamagawa et al. · Annals of Oncology · 2016 · 282 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer

Tomoya Yokota, Ken Kato, Yasuo Hamamoto et al. · British Journal of Cancer · 2016 · 146 citations · Full text

Medicine, Oncology, Surgery +14

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System

Chigusa Morizane, Nozomu Machida, Yoshitaka Honma et al. · JAMA Oncology · 2022 · 93 citations · Full text

Medicine, Oncology, Pharmacology +16

A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer

Tomoya Yokota, Ken Kato, Yasuo Hamamoto et al. · Annals of Surgical Oncology · 2019 · 60 citations

Medicine, Oncology, Surgery +9

Monolayer platform using human biopsy-derived duodenal organoids for pharmaceutical research

Tomoki Yamashita, Tatsuya Inui, Jumpei Yokota et al. · Molecular Therapy — Methods & Clinical Development · 2021 · 54 citations · Full text

Engineering, Biomedical Engineering, Tissue Engineering +2